Merck showcases oncology pipeline results at ESMO 2026
Merck highlighted first-time pivotal Phase 3 results from its oncology pipeline and the potential of its existing portfolio at ESMO 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck Showcases First — Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
For best results when printing this announcement, please click on link below: Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results